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Abstract
Background: Complementary and alternative medicine (CAM) use is prevalent among HIV-
infected patients to reduce the toxicity of antiretroviral therapy. Ginseng has been used for
treatment of hyperglycemia and insulin resistance, a common side effect of some HIV-1 protease
inhibitors (PI). However, it is unknown whether American ginseng (AG) can reverse insulin
resistance induced by the PI indinavir (IDV), and whether these two agents interact
pharmacologically. We evaluated potential pharmacokinetic interactions between IDV and AG, and
assessed whether AG improves IDV-induced insulin resistance.
Methods: After baseline assessment of insulin sensitivity using the insulin clamp technique, healthy
volunteers received IDV 800 mg q8 h for 3 days and then IDV and AG 1g q8h for 14 days. IDV
pharmacokinetics and insulin sensitivity were assessed before and after AG co-administration.
Results: There was no difference in the area-under the plasma-concentration-time curve after the
co-administration of AG, compared to IDV alone (n = 13). Although insulin-stimulated glucose
disposal per unit of insulin (M/I) decreased by an average of 14.8 ± 5.9% after 3 days of IDV (from
0.113 ± 0.012 to 0.096 ± 0.014 mg/kgFFM/min per μU/ml of insulin, p = 0.03, n = 11), M/I remained
unchanged after co-administration of IDV and AG.
Conclusion: IDV decreases insulin sensitivity, which is unaltered by AG co-administration. AG
does not significantly affect IDV pharmacokinetics.
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Background
Dietary supplements, herbs, and vitamins are used widely
among HIV-infected patients [1]. However, the safety or
efficacy of many of these therapies has not been formally
evaluated.
These agents are often used among HIV-infected patients
to prevent or treat the adverse effects of antiretroviral ther-
apy [2]. Among these adverse effects are disorders of glu-
cose metabolism, including insulin resistance[3], glucose
intolerance [4], and diabetes mellitus[3], which were
described soon after the introduction of highly active
antiretroviral therapy (HAART)[5]. Although the etiology
of these problems is multifactorial [6], exposure to pro-
tease inhibitors (PIs) likely contributes directly. Indinavir
(IDV), for example, can worsen insulin sensitivity even
after a single dose in healthy volunteers[7].
Ginseng is one of the most commonly used herbs in the
United States [8] and has long been used for the treatment
of hyperglycemia in Traditional Chinese Medicine [9].
Experimental evidence for its efficacy comes from several
studies in both animals and humans [10]. In two small
clinical trials, Panax ginseng [11] and AG [12] given daily
over 8 weeks significantly reduced fasting blood glucose
and hemoglobin A1c in patients with type 2 diabetes.
While the mechanisms by which ginseng affects glucose
metabolism have not been fully elucidated, most recent
evidence from animal models suggests that improvement
in insulin sensitivity may underlie its hypoglycemic effects
[13]. It is not known whether ginseng can reverse insulin
resistance induced by PIs.
Herbals treatments, like ginseng, are perceived to be safe
by patients, but pharmacologic interactions with concom-
itant conventional drugs are a major concern. Ginseng
was recently found to reduce the anticoagulant effect of
warfarin [14]. However, its potential interaction with
antiretrovirals has not been investigated. Other herbs,
such as St. Johns' wort [15] and garlic [16] dramatically
reduce the concentrations of PIs in healthy volunteers, in
the case of St. John's wort, through the induction of their
common metabolic pathway, cytochrome P450 3A4
(CYP450 3A4). This could lead to a decrease in effective-
ness and potentially result in treatment failure.
The goals of this study were to evaluate potential PK inter-
actions between IDV and AG, and assess whether AG
improves IDV-induced insulin resistance.
Methods
Study Participants
Healthy volunteers, male and female, 18–64 years of age,
were recruited through newspaper advertisement, flyers
and word of mouth. Exclusion criteria included a history
of nephrolithiasis, use of any prescription medications,
over the counter medications, or dietary supplement
within 14 days of enrollment, body mass index (BMI,
weight (kg)/height (m2)) ≥ 30 kg/m2, or blood donation
within 30 days of study enrollment. Prior to enrollment,
subjects were required to have a negative HIV-1 antibody
test, normal values for serum creatinine, aspartate ami-
notransferase (AST), alanine aminotransferase (ALT), and
hemoglobin, and a normal physical examination. The
study was approved by the Institutional Review Board at
Johns Hopkins University School of Medicine and all par-
ticipants signed informed consent.
Study Design
After initial screening, participants were admitted to the
Johns Hopkins inpatient General Clinical Research Center
(GCRC) on three separate occasions over a 21 day period
for PK and metabolic studies. During the first inpatient
visit, baseline insulin sensitivity was assessed. Subjects
were then discharged with instructions to take IDV 800
mg by mouth (Crixivan, Merck and Company, Rahway,
New Jersey, USA) every 8 hours (0600, 1400, 2200) on an
empty stomach beginning three days before the subse-
quent inpatient visit. During the second inpatient visit,
insulin sensitivity was reassessed and an 8-hour PK IDV
sampling was obtained. Subjects were then instructed to
take IDV, as taken previously, and to co-administer encap-
sulated AG ground root, 1 gram by mouth every 8 hours.
Outpatient safety visits with laboratory assessments
occurred 7 days before and 7 days after the final inpatient
visit.
Dried whole-root AG was obtained from a single batch
through the Wisconsin Ginseng Board (Wausau, Wiscon-
sin). The identity of the dried whole root of AG was veri-
fied by the Wisconsin ginseng Board prior to
encapsulation. Following verification the dried whole-
root AG was ground and encapsulated in 500 mg capsules
by the American Pharmaceutical Nutraceutical Laborato-
ries (Wausau, Wisconsin) and dispensed by the Johns
Hopkins Hospital Investigational Drug service. AG was
administered under Investigational New Drug Applica-
tion # 69,866 granted by the Food and Drug Administra-
tion. The dose of AG was selected based on previous
studies investigating the effect of AG on glucose tolerance
in humans[12,17]. The dose of IDV was selected accord-
ing to its package insert. Following 14 days of IDV and
AG, subjects returned to the inpatient GCRC for reassess-
ment of insulin sensitivity and IDV PK.
Ginseng Analyses
The concentrations of six common ginsenosides (Rg1, Re,
Rb1, Rc, Rb2, and Rd) were measured, following proce-
dures described by Chuang [18], in the Analytical Labora-
tory of the Johns Hopkins University Division of ClinicalBMC Complementary and Alternative Medicine 2008, 8:50 http://www.biomedcentral.com/1472-6882/8/50
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Pharmacology. Briefly, five different capsules were ran-
domly selected from five separate bottles. The content of
each capsule was extracted with 3 mL of ethanol:water
(50:50, vol:vol), sonicated, and centrifuged. The pellet
was extracted two more times and the resulting liquid was
filtered. Samples and ginsenoside standards (Sigma-
Aldrich, St. Louis, Missouri) were analyzed by High Per-
formance Liquid Chromatography (HPLC) using Beck-
man Ultrasphere 5 μm, 250 × 4.6 mm column. The
amount of each ginsenoside assayed in the capsules was as
follows (expressed as percent per gram of ginseng): Rg1
0.11, Re 1.06, Rb1 0.91, Rc 0.08, Rb2 0.19, Rd 0.08, Total
ginsenosides 2.43. The intra- and interassay coefficients of
variation (CV) were < 10.5% and < 8.5%, respectively
with > 85% accuracy.
Bioassay for Hypoglycemic Activity
The hypoglycemic activity of the batch of AG used in the
study was assessed in diabetic mice prior to initiation of
the clinical studies, as previously described [13]. Briefly,
male ob/ob mice (n = 6) received AG extract dissolved in
distilled water by daily intraperitoneal injection at a dose
of 250 mg/kg. Fasting serum glucose was measured from
blood obtained from tail samples at baseline, day 5 and
day 12. The hypoglycemic response in AG-treated mice
was compared to that observed in ob/ob mice who received
vehicle following the same protocol. Animals were fed
rodent chow and housed in environmentally stable condi-
tions in metabolic cages. Food consumption and weight
were monitored daily. All animal experiments were car-
ried out at the Tang Center for Herbal Medicine Research,
University of Chicago in the laboratory of Chun-Su Yuan,
MD, PhD.
PK Sampling and Analysis
During the second and third inpatient GCRC visits, nine
blood samples were collected immediately before admin-
istration of the morning dose of IDV and at 0.5,
1,2,3,4,5,6, and 8 hours post-dose after an overnight fast.
The previous observed dose was given at 2200. PK data
were analyzed using non-compartmental methods using
WinNonlin® (Pharsight, Cary, NC). IDV PK parameter
estimates included area under the plasma-concentration-
time curve from time 0 to 8 hours after the dose, (AUC0–8
hrs), maximum plasma concentration (Cmax), minimum
plasma concentration (Cmin), and time to maximum
plasma concentration (Tmax).
Metabolic Assessments
Body composition, including fat-free mass (FFM), was
assessed at baseline using dual x-ray absorptiometry
(Hologic-QDR 4500W, Hologic Co, Bedford, MA, intra-
subject CV < 2%). BMI was assessed during each inpatient
admission and was calculated as the weight in kilograms/
height in meters squared.
Peripheral sensitivity to glucose was assessed by the
hyperinsulinemic euglycemic clamp technique [19]. Sub-
jects were admitted to the GCRC in the afternoon prior to
the clamp procedure and maintained on a eucaloric diet
(50% carbohydrate, 30% fat, and 20% protein). After an
overnight fast, an intravenous catheter was placed in the
antecubital vein for infusion of glucose and insulin. A sec-
ond catheter for blood sampling was inserted in a dorsal
vein of the hand in a retrograde fashion. The hand was
placed into a 50°C warming box to "arterialize" the sam-
ples [20]. After baseline blood samples were obtained, a
primed, continuous infusion of regular insulin (40 mU/
m2/min) was started, followed by a constant infusion of
20% dextrose at a variable rate, based on 5-minute meas-
urements of blood glucose, in order to maintain blood
glucose concentrations at each subject's baseline level ±
5%. Infusion continued for a total of 180 minutes.
Glucose utilization (M) was calculated as the average glu-
cose infusion rate (milligrams of glucose/kilograms of
FFM/minute) during the last 60 minutes of the infusion
(i.e. steady state portion). FFM was derived from the base-
line evaluation by dual energy X-ray absorptiometry
(DXA).
During the final 60 minutes of the insulin clamp proce-
dure, samples were obtained at 10 minutes intervals to
determine insulin concentrations. M divided by the aver-
age insulin concentration in the final 60 minutes (I),
which represents the amount of glucose metabolized per
unit of insulin, was used as the primary measure of insulin
sensitivity. During the second and third inpatient visits,
the morning dose of IDV (and AG for the third inpatient
visit) was given immediately prior to the beginning of the
insulin clamp procedure. Fasting serum glucose and
homeostasis model assessment of insulin resistance
(HOMA-IR), a widely used marker of insulin sensitivity
[21], were assessed prior to the insulin clamp procedure at
each of the inpatient study visits.
The serum glucose concentration during the final 60 min-
utes of the clamp was 89.8 ± 1.0 mg/dL which was 97.8 ±
0.3% of the targeted glucose concentration with a coeffi-
cient of variation of 4.2 ± 0.3% (n = 32 clamp studies).
The average insulin concentration during the final 60
minutes of the infusion was 69.2 ± 1.7 μU/mL.
Measurements
Serum glucose was measured using the glucose oxidase
method (Beckman Instruments, Fullerton, CA). Serum
insulin concentrations were determined by enzyme
immunoassay, using a TOSOH 1800 (Tosoh Corporation,
Tokyo, Japan). Intra-assay and inter-assay CVs range from
1.4–2.3% and 5–6%, respectively. IDV concentrations
were measured by HPLC-mass spectrometry. The intra-BMC Complementary and Alternative Medicine 2008, 8:50 http://www.biomedcentral.com/1472-6882/8/50
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and inter-assay CVs were < 9% and < 8%, respectively with
> 94% accuracy.
Statistical Calculations
Paired comparisons between outcome measures obtained
during the first and second inpatients visits (i.e. Baseline
vs. IDV Condition) and during the second and third inpa-
tient visits (IDV vs IDV + AG) were made using a paired t-
test. Univariate relationships between continuous varia-
bles were assessed with linear regression. All data are pre-
sented as mean ± standard error of the mean (SEM).
Differences were regarded as statistically significant if p <
0.05. All data analysis was performed using Stata (Version
8.1, Stata Corporation, College Station, TX). Pharmacoki-
netic parameter estimates were summarized using geo-
metric means with 95% confidence intervals; values
obtained with and without AG were compared using a
geometric mean ratio and 90% confidence interval.
Results
Preclinical Studies
In ob/ob mice receiving AG extract, fasting glucose concen-
trations decreased (Baseline vs Day 12; 235 ± 11 mg/dL vs
193 ± 9 mg/dL, between group t-test, p = 0.003), but
remained constant in the vehicle-treated group (243 ± 10
mg/dL vs 251 ± 12 mg/dL) (Figure 1). Weight did not
change over the study interval in the AG-treated mice
(data not shown).
Clinical Studies
Fourteen healthy volunteers were evaluated (Table 1). All
participants were male, 12 were African-American, and
two were white. Age ranged from 26–53 years with a mean
of 42.9 ± 1.9. The average BMI was 26.1 ± 0.8 kg/m2
(range 21.9–29.9).
PK Analysis
Thirteen participants were included in the analysis of the
comparison of IDV PK with and without AG. Subject 9
was noted to develop transaminitis after the second inpa-
tient study visit and did not complete the remainder of the
study. Table 2 shows the average IDV PK parameters after
3 days of IDV following the morning dose, and after co-
administration of 14 days of IDV and AG. All PK parame-
ters were similar in the two periods.
Metabolic Studies
Insulin Sensitivity: Effect of IDV
Eleven subjects were included in the analysis to assess the
effect of IDV on insulin sensitivity. The calculated M and
M/I values for subject 4–14 is presented in Table 3. The
data from subjects 1–3 were excluded since the protocol
Fasting Glucose Concentrations in Leptin-Deficient (ob/ob) Mice Treated with AG-Extract (250 mg/kg) and Vehicle Over 12  Days (n = 6 in both groups) Figure 1
Fasting Glucose Concentrations in Leptin-Deficient (ob/ob) Mice Treated with AG-Extract (250 mg/kg) and Vehicle Over 12 
Days (n = 6 in both groups).BMC Complementary and Alternative Medicine 2008, 8:50 http://www.biomedcentral.com/1472-6882/8/50
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was changed after these subjects completed their partici-
pation in protocol. The protocol was changed to better
match peak IDV concentrations with the steady state por-
tion of hyperinsulinemia during the insulin clamp. Specif-
ically, for subjects 4 – 14, the morning dose of IDV was
administered immediately prior to the beginning of the
insulin clamp procedure, rather than two hours before the
start of the insulin clamp as originally planned and exe-
cuted for subjects 1 – 3.
Compared to baseline measurements, IDV was associated
with an average decrease in insulin sensitivity (M/I) of
14.8 ± 5.9%, from 0.113 ± 0.012 to 0.096 ± 0.014 mg/kg
FFM/min per μU/ml of insulin, p = 0.03) (Figure 2). We
also detected a decrease in average glucose utilization (M)
with IDV administration when compared to baseline
(from 7.73 ± 0.75 to 6.32 ± 0.78 mg/kg FFM/min, p =
0.005). Fasting glucose and HOMA-IR did not change
when comparing baseline to the second admission (92.4
± 1.8 mg/dL vs 95.0 ± 2.4 mg/dL, p = 0.27; 1.34 ± 0.32 vs
1.34 ± 0.23, p = 0.97, respectively).
Insulin Sensitivity: Effect of AG
Ten subjects were included to assess the effect of AG on
IDV-induced insulin resistance (Table 3). One subject
(subject 9) did not have complete data for this analysis
because he was discontinued from the study after the sec-
ond insulin clamp procedure, as previously noted. There
was no difference in insulin sensitivity between the sec-
ond (IDV alone) and third (IDV + AG) insulin clamp pro-
cedures, 0.102 ± 0.013 vs 0.099 ± 0.016 mg/kg FFM/min
per μU/ml of insulin, respectively (p = 0.72) (Figure 2).
Glucose utilization (M) with IDV administration also did
not change when AG was co-administered, 6.68 ± 0.76 vs
6.47 ± 0.84 mg/kg FFM/min, respectively (p = 0.62).
Fasting glucose and HOMA-IR did not change after 2
weeks of AG (93.0 ± 1.4 mg/dL vs 92.0 ± 2.6 mg/dL, p =
0.65; 1.4± 0.25 vs 1.4 ± 0.28, p = 0.95). Body weight did
not change during the trial (baseline vs third inpatient
study visit, 83.1 ± 3.1 kg vs 83.2 ± 3.1 kg, p = 0.88).
Insulin Sensitivity: Effect of AG after Normalization for IDV 
Concentrations
Because of the variability of IDV concentrations with and
without co-administration of AG, we evaluated the poten-
tial effect of AG on insulin sensitivity after adjustment for
IDV concentrations. In a post hoc analysis, we standardized
the measurement of insulin sensitivity for IDV concentra-
tions by dividing M/I for the second and third insulin
clamp procedures by the corresponding IDV AUC
between 2–3 hours (AUC2–3). We then multiplied this
value by 106 for ease of interpretation.
We chose the 2–3 hour IDV AUC since it is the same time
period during the clamp procedure in which insulin sen-
sitivity is assessed and there was a trend toward correla-
tion between insulin sensitivity (M/I) and IDV AUC2–3
during the third insulin clamp procedure (r = 0.58, p =
0.078). The IDV AUC2–3 was not correlated with M/I (r =
0.04, p = 0.90) during the second clamp procedure (IDV
alone). No other IDV PK parameters or other fractional
AUCs were correlated with M/I for either the second or
third clamp procedure (data not shown).
For the 10 subjects with measurable M/I estimates nor-
malized for IDV AUC2–3, the average difference in IDV
AUC2–3 was similar when comparing the period of IDV
alone to the period with concomitant IDV and AG (2353
± 389 vs 1923 ± 483 ng·hr/mL; difference: 430 ± 330
ng·hr/mL, p = 0.22). When each subject's M/I was divided
Table 2: PK parameter estimates of IDV before and after co-administration with AG (1 gram every 8 hours), n = 13
IDV alone (Day 7) 
GM (95%CI)
IDV + AG (Day 22) 
GM (95%CI)
Day 7/Day 22 
Geometric Mean Ratio 
(90% CI)
Cmax (ng/mL) 5623 (4027–7853) 5633 (4908–6464) 1.00 (0.77–1.29)
Cmin (ng/mL) 61.97 (42.72–89.88) 62.78 (39.72–99.24) 1.00 (0.77–1.29)
tmax (hours) 0.98 (0.7189–1.3403) 0.74 (0.5527–0.9870) 0.75 (0.53–1.06)
AUC0–8 (ng·h/dL) 12171 (8628–17168) 10700 (8515–13649) 0.89 (0.72–1.08)
Table 1: Demographic Characteristics of Study Participants
Subject # Race Age (years) BMI (kg/m2) Fat (%)
1A A 4 1 2 9 . 9 2 9 . 5
2A A 4 3 2 2 . 4 1 2 . 2
3A A 4 1 2 2 . 3 1 2 . 6
4A A 5 3 2 6 . 6 2 3 . 0
5 W 26 29.0 25.2
6A A 4 9 2 9 . 9 3 2 . 1
7A A 4 3 2 4 . 7 2 2 . 3
8A A 4 4 2 1 . 9 2 1 . 1
9A A 3 6 2 9 . 1 2 9 . 9
10 AA 37 24.0 24.7
11 AA 52 23.4 15.8
12 AA 42 29.3 19.7
13 AA 46 26.7 26.7
14 W 49 26.5 26.1
AA – African-American; W-WhiteBMC Complementary and Alternative Medicine 2008, 8:50 http://www.biomedcentral.com/1472-6882/8/50
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by the IDV AUC2–3, which can be interpreted as insulin
sensitivity per unit of plasma IDV, a significant increase
was seen after AG co-administration (60.9 ± 15.4 vs 92.2
± 20.9 mg Glucose·106/kg FFM/min/μU/ml of insulin/
ng·hr/mL IDV, p = 0.03). A similar increase was seen
when comparing M (multiplied times 106) divided by the
IDV AUC2–3 between the IDV alone period and the con-
comitant IDV plus AG period (4240.6 ± 1180.0 vs 6100.5
± 1526.8 mg Glucose·106/kg FFM/min/ng·hr/mL IDV, p
= 0.05).
Safety Assessment
Both IDV and AG were well tolerated. There were no seri-
ous adverse events. Three subjects developed transamini-
tis. In one subject (as previously mentioned), an AST
elevation 3 times the upper limit of normal (Grade 2)
after 3 days of IDV required study discontinuation. Three
subjects were noted to have mild elevations in bilirubin.
One subject had a mild increase in serum creatinine. One
patient reported an episode of vomiting and one subject
reported dyspepsia after dose administration. All labora-
tory abnormalities and symptoms normalized after dis-
continuation of the study drugs. With the exception of the
Grade 2 transaminites, all adverse events occurred during
the co-administration of IDV and AG.
Adherence Assessment
By pill count assessed on three occasions during the study
(i.e., the second and third inpatient visit and the interven-
ing outpatient safety visit), IDV overall mean adherence
was 97.7 ± 1.5%. AG adherence, as assessed on two occa-
sions (interim outpatient visit and visit three), was 96.6 ±
2.5%.
Discussion
In this prospective study of healthy volunteers, we found
that 14 days of co-administration of AG did not signifi-
cantly impact IDV PK. We also found that, although IDV
acutely reduced insulin sensitivity by an average of 15%,
AG did not change insulin sensitivity in IDV-treated
healthy volunteers, providing evidence against its use in
the treatment of PI-induced disorders of glucose metabo-
lism.
Potential drug-herb interactions are an important safety
concern for many clinicians and HIV-infected patients.
Although herbal remedies are perceived as safe by many
patients, some can inhibit and/or induce the CYP3A4
enzyme, the main metabolic pathway for most PIs and
non-nucleoside reverse transcriptase inhibitors (NNRTIs),
potentially leading to increased toxicity or therapeutic
failure [15,16]. The metabolic pathways of ginseng com-
ponents are not well known. Ginsenosides, which are ster-
oid-like molecules of the saponin class, are thought to be
the active compounds of all ginseng species [22]. There
are more than 20 different types of ginsenosides in gin-
seng root and their relative concentrations varies depend-
ing on the species, the batch, and the part of the plant
assayed (eg. root vs berry)[23,24]. The ginsenosides also
differ in their effects on metabolism. In in vitro models
investigating the catalytic activity of c-DNA expressed
CYP450 isoforms, the ginsenoside, Rd, has been shown to
be a weak inhibitor of CYP3A4, while Rf increased
CYP3A4 activity by 54% [25]. In addition, metabolites of
ginsenosides as well as non-ginsenoside components of
ginseng have also been shown to inhibit CYP3A4 in exper-
imental models [26,27]. The clinical significance of these
in vitro observations is not clear.
Table 3: Glucose Utilization (M) and Insulin  Sensitivity (M/I) Measured by the Hyperinsulinemic Euglycemic Clamp in  Healthy 




(mg/kg FFM/min per μU/ml of insulin)
Baseline IDV Alone IDV + AG Baseline IDV Alone IDV + AG
4 8.25 5.69 5.79 0.121 0.072 0.072
5 8.46 8.20 10.35 0.135 0.138 0.193
6 4.58 3.93 4.01 0.055 0.049 0.059
7 11.52 7.14 7.82 0.173 0.141 0.134
8 8.88 9.02 7.29 0.132 0.155 0.118
9 4.10 2.74 - 0.062 0.037 -
10 10.14 9.54 9.94 0.119 0.126 0.123
11 9.60 8.62 5.93 0.157 0.115 0.107
12 6.19 4.24 3.51 0.078 0.062 0.042
13 8.62 7.82 7.66 0.137 0.123 0.113
14 4.60 2.62 2.37 0.068 0.038 0.030BMC Complementary and Alternative Medicine 2008, 8:50 http://www.biomedcentral.com/1472-6882/8/50
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In previous human studies, Siberian ginseng (Eleutherococ-
cus senticosus) has been shown to increase concentrations
of nifedipine [28], a CYP3A4 substrate, but does not affect
concentrations of midazolam [29], another CYP3A4
probe drug. It should be noted that Siberian ginseng is not
a species of the genus Panax, contains no ginsenosides,
and therefore the effects of Siberian ginseng are not gener-
alizable to members of the Panax genus, such as AG. How-
ever, human studies in healthy volunteers using Panax
ginseng  (C.A. Meyer) have shown no interaction with
midazolam [30] and no change in urinary 6-beta-OH-cor-
tisol/cortisol ratio [31], both measures of CYP3A4 activ-
ity.
We also found that 3 days of IDV administration
decreased insulin sensitivity by 15% in healthy volun-
teers. Our findings are similar to another healthy volun-
teer study, showing a 17% decrease in insulin sensitivity
with IDV administration (800 mg q 8 hours)[32], but
smaller in magnitude when compared to another study
using a higher dose (34% decrease with a single dose of
1200 mg) [33]. In in vitro studies and animal models, PIs,
such as IDV, impede glucose movement through the
major glucose transporter in skeletal muscle, GLUT4,
thereby inducing insulin resistance[34]. The observations
in humans, including ours, are consistent with this mech-
anism, although the extent to which it is clinically relevant
in the pathogenesis of hyperglycemia among HIV-
infected, HAART-treated patients remains unclear.
Although we observed that insulin sensitivity decreased
with IDV administration, we did not find any change in
Insulin Sensitivity (Glucose Infusion Rate Per Kilogram of Free-Fat Mass Per Unit of Insulin) at Baseline, After Figure 2
Insulin Sensitivity (Glucose Infusion Rate Per Kilogram of Free-Fat Mass Per Unit of Insulin) at Baseline, After 3 Days of Indina-
vir, and After 14 Days of Co-Administration of AG in Healthy Volunteers (p-values represent the average mean difference by 
paired t-test).BMC Complementary and Alternative Medicine 2008, 8:50 http://www.biomedcentral.com/1472-6882/8/50
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insulin sensitivity with co-administration of AG. In previ-
ous studies, Vuksan, et al. showed that AG administration
immediately prior to an oral glucose tolerance test was
associated with 20% decrease in glucose AUC in both
patients with type 2 diabetes mellitus and healthy volun-
teers [35], but this effect appears to be dependent on the
batch of ginseng used [23]. To rule out an inert batch of
AG, we conducted a bioassay of our batch using an ob/ob
mouse model and a hypoglycemic effect was observed,
suggesting that our batch possessed some active compo-
nents.
The mechanism underlying the previously observed
effects of AG on glucose metabolism remains unknown
and may be multifactorial. The modulation of digestion
and enhancement of insulin secretion have been pro-
posed based on findings in some animals models [36,37],
but ginseng administration has also been shown to
improve insulin sensitivity in ob/ob mice by more than
two-fold [13]. It has been postulated that ginsenosides
may intercalate into the cellular plasma membrane, thus
modulating the cell signaling, electrolyte transport, and
receptor binding [22]. It is not known whether this effect
could also modulate the effect of IDV on the glucose flux
through the GLUT4 transporter.
Another factor that may have contributed to the lack of
effect is the variability of IDV plasma concentrations
between the two clamps, which has been previously
observed [38]. The effect of AG on IDV-induced insulin
resistance would be best determined if IDV plasma con-
centrations were the same when it was given alone and
when it was co-administered with AG. For this reason, we
normalized the measure of insulin sensitivity for drug
concentration in a post hoc analysis, by dividing M/I by the
IDV concentration during the steady state portion of the
clamp and found that this ratio was significantly higher in
the IDV + AG condition.
Although the interpretation of ratios can be challenging
[39] and should be done with caution, one explanation of
this finding is that insulin sensitivity per unit of IDV con-
centration modestly improved with the administration of
AG. Given the known effect of IDV on GLUT4 blockade,
AG components may work directly at the plasma mem-
brane to allow glucose to enter cells, either by improving
glucose movement through GLUT4, increasing the con-
centration of GLUT4 in the plasma membrane, or facili-
tating glucose entry through alternate pathways. Another
possible mechanism of AGs effect may be through the
enhancement of local blood flow. Increased capillary
recruitment mediated though nitric oxide is an important
mechanism of increasing glucose and insulin delivery to
skeletal muscle [40,41]. IDV has been shown to cause
endothelial dysfunction in healthy volunteers, likely by
reducing nitric oxide production [42]. Ginseng species
have been shown in experimental models to increase
nitric oxide production [43,44] and therefore, may effect
insulin sensitivity by this mechanism. This hypothesis
requires further investigation.
Our study had additional limitations which may have
implications for the generalizability of its findings.
Although both men and women were eligible for partici-
pation, only men enrolled. In previous studies, inducibil-
ity of CYP3A4 by herbal compounds has shown an
interaction by sex, whereby women showed a 74%
increased effect of St. John's wort on CYP3A4 activity
using a midazolam probe compared to men [45]. In the
same study, however, Panax ginseng showed no effect on
the midazolam metabolism in either men or women. Fur-
ther PK interaction studies in women may be necessary. In
addition, our population was mostly African-American.
Although there is evidence for genotypic differences in
CYP3A4 between Caucasians and African-Americans, phe-
notypic differences in CYP3A4 activity have not been
found [46]. Finally, although we quantified the amount of
common ginsenosides, there is substantial variability of
composition even within species. As a result, as is the case
in all botanical research using non-standardized complex
compounds whose active component is unknown, the
extent to which our findings are generalizable to other AG
products is not clear.
In conclusion, this study in healthy volunteers found no
evidence of a significant PK interaction between AG and
IDV. Because CYP3A4 is the principal metabolic pathway
of most HIV PIs and NNRTIs, significant drug-herb inter-
actions with these antiretrovirals are unlikely. The meta-
bolic effects of AG are more difficult to interpret.
Although IDV significantly reduced insulin sensitivity,
there was no change in insulin sensitivity with AG admin-
istration. However, after normalization for IDV concen-
trations, insulin sensitivity improved in the AG condition,
leaving open the possibility of a modest effect on glucose
metabolism. Further studies to clarify this question
should attempt to reduce variability in IDV plasma con-
centrations, either by giving multiple doses of IDV at
shorter intervals to maintain plasma IDV concentrations
constant while insulin sensitivity is assessed, or using an
IDV regimen boosted with ritonavir. Until these issues are
resolved, there is no clear scientific basis to recommend
AG for the treatment of glucose abnormalities in HIV-
infected patients.
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